Ofatumumab: a novel monoclonal anti-CD20 antibody

Ofatumumab: a novel monoclonal anti-CD20 antibody

Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC). Pha...

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

INTRODUCTION Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established. CASE REPORT The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a r...

Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody

Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia.

© 2010 The Authors. doi: 10.2340/00015555-0762 Journal Compilation © 2010 Acta Dermato-Venereologica. ISSN 0001-5555 Sir, Patients with leukaemia are at high risk of developing cutaneous or invasive opportunistic infections caused by unusual bacteria of low virulence or by fungi. Immunosuppression is related to the malignancy itself and/or the therapies. We report here an atypical presentation ...

Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling

Background: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody...